Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells
In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in immunologic benefit, despite virologic failure. In such patients, two protease mutations, I54V and V82A, occur more frequently. Expressing HIV protease containing these mutations resulted in less cell death, caspase activation, and nuclear fragmentation than wild type (WT) HIV protease or HIV protease containing other mutations. The impaired induction of cell death was also associated with impaired cleavage of procaspase 8, a requisite event for HIV protease mediated cell death. Primary CD4 T cells expressing I54V or V82A protease underwent less cell death than with WT or other mutant proteases. Human T cells infected with HIV containing these mutations underwent less cell death and less Casp8p41 production than WT or HIV containing other protease mutations, despite similar degrees of viral replication. The reductions in cell death occurred both within infected cells, as well as in uninfected bystander cells. These data indicate that single point mutations within HIV protease which are selected in vivo can significantly impact the ability of HIV to kill CD4 T cells, while not impacting viral replication. Therefore, HIV protease regulates both HIV replication as well as HIV induced T cell depletion, the hallmark of HIV pathogenesis.
Vyšlo v časopise:
Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells. PLoS Pathog 6(11): e32767. doi:10.1371/journal.ppat.1001213
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1001213
Souhrn
In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in immunologic benefit, despite virologic failure. In such patients, two protease mutations, I54V and V82A, occur more frequently. Expressing HIV protease containing these mutations resulted in less cell death, caspase activation, and nuclear fragmentation than wild type (WT) HIV protease or HIV protease containing other mutations. The impaired induction of cell death was also associated with impaired cleavage of procaspase 8, a requisite event for HIV protease mediated cell death. Primary CD4 T cells expressing I54V or V82A protease underwent less cell death than with WT or other mutant proteases. Human T cells infected with HIV containing these mutations underwent less cell death and less Casp8p41 production than WT or HIV containing other protease mutations, despite similar degrees of viral replication. The reductions in cell death occurred both within infected cells, as well as in uninfected bystander cells. These data indicate that single point mutations within HIV protease which are selected in vivo can significantly impact the ability of HIV to kill CD4 T cells, while not impacting viral replication. Therefore, HIV protease regulates both HIV replication as well as HIV induced T cell depletion, the hallmark of HIV pathogenesis.
Zdroje
1. CollazosJ
AsensiV
CartonJA
2009 CD4 responses in the setting or suboptimal virological responses to antiretroviral therapy: features, outcomes, and associated factors. AIDS Res Hum Retroviruses 25 647 655
2. GrabarS
Le MoingV
GoujardC
LeportC
KazatchkineMD
2000 Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133 401 410
3. TuboiSH
BrinkhofMW
EggerM
StoneRA
BraitsteinP
2007 Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 45 52 59
4. PitrakDL
BolanosJ
HershowR
NovakRM
2001 Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. Aids 15 1317 1319
5. SolomonA
LaneN
WightmanF
GorryPR
LewinSR
2005 Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts. J Acquir Immune Defic Syndr 40 140 148
6. LecossierD
BouchonnetF
SchneiderP
ClavelF
HanceAJ
2001 Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 183 1009 1016
7. D'EttorreG
ForcinaG
AndreottiM
SarmatiL
PalmisanoL
2002 Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production. Aids 16 1877 1885
8. PriceDA
ScullardG
OxeniusA
BraganzaR
BeddowsSA
2003 Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. J Virol 77 6041 6049
9. SufkaSA
FerrariG
GryszowkaVE
WrinT
FiscusSA
2003 Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis 187 1027 1037
10. KaplanSS
FerrariG
WrinT
HellmannNS
TomarasGD
2005 Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. AIDS Res Hum Retroviruses 21 13 16
11. SchechterM
TuboiSH
2006 Discordant immunological and virological responses to antiretroviral therapy. J Antimicrob Chemother 58 506 510
12. van GriensvenJ
ZachariahR
RasschaertF
ReidT
2009 Discordant immunologic and virologic responses to antiretroviral therapy and associated mortality in a large treatment program in Rwanda. J Acquir Immune Defic Syndr 50 556 558
13. DeeksSG
WrinT
LieglerT
HohR
HaydenM
2001 Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344 472 480
14. VarbanovM
EspertL
Biard-PiechaczykM
2006 Mechanisms of CD4 T-cell depletion triggered by HIV-1 viral proteins. AIDS Rev 8 221 236
15. KaplanAH
SwanstromR
1991 Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A 88 4528 4532
16. NieZ
PhenixBN
LumJJ
AlamA
LynchDH
2002 HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 9 1172 1184
17. NieZ
BrenGD
VlahakisSR
SchimnichAA
BrenchleyJM
2007 Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo. J Virol 81 6947 6956
18. Algeciras-SchimnichA
Belzacq-CasagrandeA
BrenGD
NieZ
TaylorJA
2007 Analysis of HIV protease killing through Caspase 8 reveals a novel interaction between caspase 8 and mitochondria. The Open Virology Journal 1 39 46
19. CumminsNW
JiangW
McGintyJ
BrenGD
BoschRJ
2010 Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis 202 386 391
20. NieZ
BrenGD
RizzaSA
BadleyAD
2008 HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells. Open Virol J 2 1 7
21. NijhuisM
SchuurmanR
de JongD
EricksonJ
GustchinaE
1999 Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. Aids 13 2349 2359
22. Hawley-FossN
MbisaG
LumJJ
PilonAA
AngelJB
2001 Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. Clin Infect Dis 33 344 348
23. MeroniL
VarchettaS
ManganaroD
GattiN
RivaA
2002 Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors. J Infect Dis 186 143 144
24. RoseJR
BabeLM
CraikCS
1995 Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol 69 2751 2758
25. ZhangQ
RaoofM
ChenY
SumiY
SursalT
2010 Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464 104 107
26. HuntPW
DeeksSG
BangsbergDR
MossA
SinclairE
2006 The independent effect of drug resistance on T cell activation in HIV infection. Aids 20 691 699
27. PennML
MyersM
EcksteinDA
LieglerTJ
HaydenM
2001 Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses 17 517 523
28. StoddartCA
LieglerTJ
MammanoF
Linquist-SteppsVD
HaydenMS
2001 Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 7 712 718
29. LucasGM
2005 Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother 55 413 416
30. Martinez-PicadoJ
SavaraAV
SuttonL
D'AquilaRT
1999 Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 73 3744 3752
31. Manosuthi W, Butler DM, Perez-Santiago J, Poon AF, Pillai SK, et al. Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure. Aids 24 411 416
32. ChunTW
CarruthL
FinziD
ShenX
DiGiuseppeJA
1997 Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 183 188
33. HarperME
MarselleLM
GalloRC
Wong-StaalF
1986 Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A 83 772 776
34. CostigliolaP
TumiettoF
RicchiE
ChiodoF
1992 Detection of circulating p24 antigen-positive CD4+ cells during HIV infection by flow cytometry. Aids 6 1121 1125
35. MarechalV
ClavelF
HeardJM
SchwartzO
1998 Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 72 2208 2212
36. RiggRJ
DandoJS
EscaichS
PlavecI
BohnleinE
1995 Detection of intracellular HIV-1 Rev protein by flow cytometry. J Immunol Methods 188 187 195
37. BrockmanMA
TanziGO
WalkerBD
AllenTM
2006 Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry. J Virol Methods 131 134 142
38. ZhouY
ZhangH
SilicianoJD
SilicianoRF
2005 Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 79 2199 2210
39. CarterCC
Onafuwa-NugaA
McNamaraLA
RiddellJt
BixbyD
2010 HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16 446 451
40. GangeSJ
SchneiderMF
GrantRM
LieglerT
FrenchA
2006 Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. J Acquir Immune Defic Syndr 41 68 74
41. IzopetJ
MarchouB
CharreauI
SauneK
TangreP
2008 HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response. Antivir Ther 13 537 545
42. RodesB
GarciaF
GutierrezC
Martinez-PicadoJ
AguileraA
2005 Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. J Med Virol 77 23 28
43. HertogsK
de BethuneMP
MillerV
IvensT
SchelP
1998 A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42 269 276
44. JayaramanS
2005 Flow cytometric determination of mitochondrial membrane potential changes during apoptosis of T lymphocytic and pancreatic beta cell lines: comparison of tetramethylrhodamineethylester (TMRE), chloromethyl-X-rosamine (H2-CMX-Ros) and MitoTracker Red 580 (MTR580). J Immunol Methods 306 68 79
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2010 Číslo 11
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Zn Inhibits Coronavirus and Arterivirus RNA Polymerase Activity and Zinc Ionophores Block the Replication of These Viruses in Cell Culture
- The Female Lower Genital Tract Is a Privileged Compartment with IL-10 Producing Dendritic Cells and Poor Th1 Immunity following Infection
- Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41
- The Arabidopsis Resistance-Like Gene Is Activated by Mutations in and Contributes to Resistance to the Bacterial Effector AvrRps4